Title: Outcome of Sofosbuvir and Ribavirin based treatment in genotype 3 of cirrhotic chronic hepatitis C patients
Authors: Raese Noor Khan, Aadil Bashir Rather, Mohsin Rashid, Prof. Gul Javaid
DOI: https://dx.doi.org/10.18535/jmscr/v7i4.141
Abstract
Introduction: Hepatitis C virus is a leading cause of chronic liver disease in both industrialized and developing countries. Considering the high prevelance of chronically infected individuals, the burden of disease and the absence of a vaccine, treatment forms part of the control of the disease. Sofosbuvir is a pyrimidine nucleotide analogue with high anti-viral activity against all genotypes and shows a high genetic barrier to resistance
Aims and Objectives: The aim of this study is to assess the Outcome of Sofosbuvir and Ribavirin based treatment in genotype 3 of cirrhotic chronic hepatitis C patients.
Materials and Methods: This was a prospective study carried in the department of Gastroenterology Sheri Kashmir Institute of medical sciences soura between 2015 to 2016 involving chronic cirrhotic hepatitis C patients of Genotype 3 with age more than 18yrs. Data analysis was performed using the IBM SPSS version 22.
Results and Observations: In this prospective study the total number of patients was (n=29). The mean age (in years) of patients was (41.2 ±11.77). The number of male patients was 11 (37.93%) and of female patients wa18s (62.06%). The number of cirrhotic patients in treatment naïve group was (n=23) while that in treatment experienced group was (n=6).On comparison on the basis of sustained virological response at twelve weeks of the completion of treatment (SVR12) we observed that treatment naïve cirrhotic patients had (SVR12=100%) while in the treatment experienced non cirrhotic patients (SVR12=66.7%).Sustained virological response (SVR12) among male and female patients was statistically not significant.
Conclusion: The sofosbuvir and ribavirin based therapy shows potentially good rates of sustained virological response in patients with chronic hepatitis C genotype 3 patients and is cost effective and easy to adminster.
Keywords: Hepatitis C; Genotype 3;treatment.
References
- Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57: 1333–1342.
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–115.
- Simmonds P, Bukh J, Combet C,et al. Consensus proposals for aunified system of nomenclature ofhepatitis C virus genotypes. Hepatology 2005; 42: 962–
- Shepard CW, Finelli L, Alter MJ.Global epidemiology of hepatitis Cvirus infection. Lancet Infect Dis2005; 5: 558–
- Ghany MG, Strader DB, Thomas DL,Seeff LB. Diagnosis, management, andtreatment of hepatitis C: an update.Hepatology 2009; 49: 1335–
- Herbst DA Jr, Reddy KR. Sofosbuvir,a nucleotide polymerase inhibitor, forthe treatment of chronic hepatitis Cvirus infection. Expert OpinInvestigDrugs 2013; 22: 527–
- Rodr_ıguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-actingantiviral for hepatitis C virusinfection. Expert Rev Anti Infect Ther2013; 11: 1269–
- Lawitz E, Lalezari JP, HassaneinT,et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin fornon-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3hepatitis C infection: a randomised,double-blind, phase 2 trial. LancetInfect Dis2013;
- Sovaldi (sofosbuvir) tablets: USprescribing information. Foster City,CA: Gilead Sciences, 2013.
- Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med.2014;370:1993-2001.
- Foster GR, et al. N Engl J Med. 2015;373:2608-17
- Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149: 1462-70.
- Jacobson IM etal, Nejm 2013May 16:386(20).
- Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-77